M V 1 2 3 4 5 6 7 8 9 10 11 12 13 14 (bp)
4 K 3 K
2 K 1.5 K 1 K 750 500 250
圖二、1％的瓊脂糖膠分析，以pET 20b作為控制組相較於實驗組是否已接入grouper IgM CH2-CH4基因片段。
Lane M : marker。
Lane V: pET 20b。
Lane 1-14: pET 20b-grouper IgM CH2-CH4 ligation plasmid 1、9、12、13、14、15、16、18、
20、23、24、25、27、29號。
M 1 2 (bp)
4 K 3 K 2 K 1.5 K 1 K 750 500 250
圖三、1％ 的瓊脂糖膠分析，以酵素 Hind III 和 Xho I 作用證實實驗組中 12 和 24 號以 pET20b 為載體，已成功接入 grouper IgM CH2-CH4 基因片段，其分子量大約 1 kb。
Lane M : marker。
Lane 1: digest pET20b-grouper IgM CH2-CH4 ligation plasmid 12號。
Lane 2: digest pET20b-grouper IgM CH2-CH4 ligation plasmid 24號。
M V 1 2 3 4 5 6 7 (bp)
4 K 3 K 1.5 K2 K
1 K 750 500 250
圖四、1％ 的瓊脂糖膠分析，以 pET 20b grouper-IgM CH2-CH4 plasmid 作為控制組相較於 實驗組是否已接入 HB56 中 Fab 的 heavy chain的基因片段。
Lane M : marker。
Lane V: pET 20b grouper-IgM CH2-CH4 plasmid。
Lane 1-7: pET 20b heavy chain of HB56 Fab-grouper IgM CH2-CH4 ligation plasmid 1、2、3、5、
6、9、10號。
M 1 2 3 (bp)
4 K 3 K 2.5 K
2 K 1.5 K 1 K 750 500 250
圖五、1％ 的瓊脂糖膠分析，以酵素 NdeⅠ 和 Hind III 作用證實實驗組中 1、9、10 號 以 pET 20b grouper-IgM CH2-CH4 plasmid 作為載體已成功接入 HB56 中 Fab 的 heavy chain 基因片段，其分子量大約 0.7 kb。
Lane M : marker。
Lane 1-3: digest pET 20b heavy chain of HB56 Fab-grouper IgM CH2-CH4 ligation plasmid 1號、9 號、10號。
M V 1 (bp)
4 K 3 K 2.5 K
2 K 1.5 K 1 K 750 500 250
圖六、1％ 的瓊脂糖膠分析，以 pET 23a 作為控制組相較於實驗組是否已接入 HB56 light chain (LC) 基因片段。
Lane M : marker。
Lane V: pET 23a。
Lane 1: pET 23a-HB56 light chain ligation plasmid 27 號 。
M 1 (bp)
4 K 3 K 2.5 K
2 K 1.5 K 1 K 750 500 250
圖七、1％ 的瓊脂糖膠分析，以酵素 NdeⅠ 和 Hind III 作用證實實驗組中 27 號以 pET23a 為載體已成功接入 HB56 light chain (LC) 基因片段，其分子量大約 0.7 kb。
Lane M : marker。
Lane 1: digest pET 23a-HB56 light chain ligation plasmid 27號。
M V 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 (bp)
4 K 3 K 2.5 K
2 K 1.5 K 1 K 750 500 250
圖八、1％ 的瓊脂糖膠分析，以 pSecTaq2A 作為控制組相較於實驗組是否已接入 chimeric heavy chain 基因片段-1。
Lane M : marker。
Lane V: pSecTaq2A。
Lane 1-15: pSecTaq2A-chimeric heavy chain ligation plasmid 1、2、3、4、5、6、7、8、9、10、
11、12、13、14、15 號。
(bp)
4 K 3 K 2.5 K 1.5 K2 K
1 K 750 500
M V 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
圖九、1％ 的瓊脂糖膠分析，以 pSecTaq2A 作為控制組相較於實驗組是否已接入 chimeric heavy chain 基因片段-2。
Lane M : marker。
Lane V: pSecTaq2A。
Lane 1-15: pSecTaq2A-chimeric heavy chain ligation plasmid 16、17、18、19、20、21、22、
23、24、25、26、27、28、29、30號。
M 1 2 3 4 5 6 7 8 9 10 11 12 (bp)
4 K 3 K 2.5 K
2 K 1.5 K 1 K 750 500 250
圖十、1％ 的瓊脂糖膠分析，以酵素 Asc I 和 Xho I 作用證實實驗組中 2、3、6、7、8、
11、17、18、20、25、26 號以 pSecTaq2A 作為載體已成功接入 chimeric heavy chain 基因 片段，其分子量大約 1.7 kb。
Lane M : marker。
Lane 1-12: digest pSecTaq2A-chimeric heavy chain ligation plasmid 2、3、6、7、8、11、17、
18、20、25、26、27號。
M V 1 2 3 4 5 (bp)
4 K 3 K 2.5 K
2 K 1.5 K 1 K 750 500 250
圖十一、1％ 的瓊脂糖膠分析，以 pSecTaq2B 作為控制組相較於實驗組是否已接入 HB56 light chain (LC) 基因片段。
Lane M : marker。
Lane V: pSecTaq2B。
Lane 1-5: pSecTaq2B-HB56 light chain ligation plasmid 7、11、16、18、20 號。
M 1 2 3 4 (bp)
4 K 3 K 2.5 K
2 K 1.5 K 1 K 750 500 250
圖十二、1％ 的瓊脂糖膠分析，以酵素 Hind III 和 Xho I 作用證實實驗組中 11、16、20 號以 pSecTaq2B 作為載體已成功接入 HB56 light chain (LC) 基因片段，其分子量大約 0.7 kb。
Lane M : marker。
Lane 1-4: digest pSecTaq2B-HB56 light chain ligation plasmid 11、16、18、20 號。
M V 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 (bp)
4 K 3 K 2.5 K
2 K 1.5 K 1 K 750 500
圖十三、1％ 的瓊脂糖膠分析，以 pEGFP-N1 作為控制組相較於實驗組是否已接入 pSecTaq2B-HB56 light chain (LC) 基因片段-1。
Lane M : marker。
Lane V: pEGFP-N1。
Lane 1-15: pEGFP-N1-pSecTaq2B-HB56 light chain ligation plasmid 1、2、3、4、5、6、7、8、
9、10、11、12、13、14、15號。
M V 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 (bp)
4 K 3 K 2.5 K
2 K 1.5 K 1 K750 500 250
圖十四、1％ 的瓊脂糖膠分析，以 pEGFP-N1 作為控制組相較於實驗組是否已接入 pSecTaq2B-HB56 light chain (LC) 基因片段-2。
Lane M : marker。
Lane V: pEGFP-N1。
Lane 1-15: pEGFP-N1-pSecTaq2B-HB56 light chain ligation plasmid 16、17、18、19、20、21、
22、23、24、25、26、27、28、29、30 號。
M 1 2 3 4 5 6 7 8 9 10 11 12 13 14 (bp)
4 K 3 K 2.5 K
2 K 1.5 K 1 K750
500
圖十五、1％ 的瓊脂糖膠分析，以酵素 Nhe I 和 EcoR I 作用證實實驗組中 2、5、6、7、
9、10、14、15、16、17、22、25、27、29 號以 pEGFP-N1 為載體已成功接入 pSecTaq2B-HB56 light chain (LC) 基因片段，其分子量大約 1.2 kb。
Lane M : marker。
Lane 1-14: digest pEGFP-N1-pSecTaq2B-HB56 light chain ligation plasmid 2、5、6、7、9、10、
14、15、16、17、22、25、27、29 號。
M V 1 (bp)
6 K5 K 4 K 3 K 2.5 K
2 K 1.5 K 1 K 750 500
圖十六、1％ 的瓊脂糖膠分析，以 pEGFP-N1-pSecTaq2B-HB56 light chain (LC) plasmid 作 為控制組相較於實驗組是否已接入 pSecTaq2A-chimeric heavy chain 基因片段。
Lane M : marker。
Lane V: pEGFP-N1-pSecTaq2B-HB56 light chain plasmid。
Lane 1: p-N1-pSecTaq2B-HB56 light chain-pSecTaq2A-chimeric heavy chain ligation plasmid 1 號。
M 1 (bp)
6 K5 K 4 K 2.5 K3 K
2 K 1.5 K
1 K 750
圖十七、1％ 的瓊脂糖膠分析，以酵素 Kpn I 和 Not I 作用證實實驗組中 1 號以 pEGFP-N1-pSecTaq2B-HB56 light chain plasmid 為載體已成功接入 pSecTaq2A-chimeric heavy 基因片段，其分子量大約 2.5 kb。
Lane M : marker。
Lane 1: digest p-N1-pSecTaq2B-HB56 light chain-pSecTaq2A-chimeric heavy chain ligation plasmid 1 號。
圖十八、擬魚化抗體載體。將小鼠單株抗體輕鏈與嵌合的重鏈 (鼠源單株抗體 Fab 片段中 重鏈的部份融合魚類 IgM Fc 片段) 基因構築至同一個真核表現的載體中，由各自的 CMV promoter 表現同等量的蛋白質再由 signal sequence 分泌至培養液中，同時並藉由真核系統 修飾形成完整的抗體。
參考文獻
1. 臺灣魚類資料庫。http://www.fish.org.tw/chinese/intro.htm (accessed Jul 8, 2008)。
2. 陳宗嶽。石斑魚病原與病原反應功能基因研究。
7. Arimoto, M., Mushiake, K., Mizuta, Y., Nakai, T., Muroga, K. & Furusawa, I. Detection of striped jack nervous necrosis virus (SJNNV) by enzyme-linked immunosorbent assay (ELISA). Fish Pathol. 27, 191-195 (1992).
8. Akabani, G., Cokgor, I., Coleman, R. E., Gonzalez Trotter, D., Wong, T. Z., Friedman, H. S., Friedman, A. H., Garcia-Turner, A., Herndon, J. E., DeLong, D., McLendon, R. E., Zhao, X.
G., Pegram, C. N., Provenzale, J. M., Bigner, D. D. & Zalutsky, M. R. Dosimetry and dose-response relationships in newly diagnosed patients with malignant gliomas treated with iodine-131-labeled anti-tenascin monoclonal antibody 81C6 therapy. Int. J. Radiat. Oncol.
Biol. Phys. 46, 947-958 (2000).
9. Aoyama, T., Kamata, K., Yamanaka, N., Takeuchi, Y., Higashihara, M. & Kato, S.
Characteristics of polyclonal anti-human nephrin antibodies induced by genetic immunization using nephrin cDNA. Nephrol. Dial. Transplant. 4, 1073-1081 (2006).
10. Atwell, J. L., Pearce, L. A., Lah, M., Gruen, L. C., Kortt, A. A. & Hudson, P. J. Design and expression of a stable bispecific scFv dimer with affinity for both glycophorin and N9 neuraminidase.Mol. Immunol. 17, 1301-1312 (1996).
11. Bloch, B., Gravningen, K. & Larsen, J. L. Encephalomyelitis among turbot associated with a picornavirus-like agent. Dis. Aquat. Organ. 10, 65-70 (1991).
12. Bird, R. E., Hardman, K. D., Jacobson, J. W., Johnson, S., Kaufman, B. M., Lee, S. M., Lee, T., Pope, S. H., Riordan, G. S. & Whitlow, M. Single-chain antigen binding proteins.
Science 242, 423-426 (1988).
13. Brinkmann, U., Reiter, Y., Jung, S. H., Lee, B. & Pastan, I. A recombinant immunotoxin containing a disulfide-stabilized Fv fragment. Proc. Natl. Acad. Sci. U. S. A. 90, 7538-7542 (1993).
14. Better, M., Bernhard, S. L., Lei, S. P., Fishwild, D. M., Lane, J. A., Carroll, S. F. & Horwitz, A. H. Potent anti-CD5 ricin A chain immunoconjugates from bacterially produced Fab’ and F(ab’)2. Proc. Natl. Acad. Sci. U. S. A. 90, 457-461 (1993).
15. Benvenuto, E. & Tavladoraki, P. Immunotherapy of plant viral diseases. Trends. Microbiol.
3, 272-275 (1995).
16. Colcher, D., Milenic, D. E., Ferroni, P., Carrasquillo, J. A., Reynolds, J. C., Roselli, M., Larson, S. M. & Schlom, J. In vivo fate of monoclonal antibody B72.3 in patients with colorectal cancer. J. Nucl. Med. 31, 1133-1142 (1990).
17. Chester, K. A. & Hawkins, R. E. Clinical issues in antibody design. Trends. Biotechnol. 13, 294-300 (1995).
18. Covell, D. G., Barbet, J., Holton, O. D., Black, C. D., Parker, R. J. & Weinstein, J. N.
Pharmacokinetics of monoclonal immunoglobulins G1, F(ab’)2, and Fab’ in mice. Cancer Res. 46, 3969 (1986).
19. Chi, S. C., Lo, F., Kou, G. H., Chang, P. S., Peng, S. E. & Chen, S. N. Mass mortalities associated with viral nervous necrosis (VNN) disease in two species of hatchery-reared grouper, Epinephelus fuscogutatus and Epinephelus akaara (Temminck & Schlegel). J. Fish Dis. 20, 185-193 (1997).
20. Comps, M., Trindade, M. & Delsert, C. Investigation of fish encephalitis viruses (FEV) expression in marine fishes using DIG-labelled probes. Aquaculture 143, 113-121 (1996).
21. Colcher, D., Goel, A., Pavlinkova, G., Beresford, G., Booth, B. & Batra, S. K. Effects of genetic engineering on the pharmacokinetics of antibodies. Q. J. Nucl. Med. 43, 132-139 (1999).
22. Chen, J. D., Yang, Q., Yang, A. G., Marasco, W. A. & Chen, S. Y. Intraand extracellular immunization against HIV-1 infection with lymphocytes transduced with an AAV vector expressing a human anti-gp120 antibody. Hum. Gene Ther. 7, 1515-1525 (1996).
23. Chen, S. Y., Bagley, J. & Marasco, W. A. Intracellular antibodies as a new class of therapeutic molecules for gene therapy. Hum. Gene Ther. 5, 595-601 (1994a).
24. Chen, S. Y., Khouri, Y., Bagley, J. & Marasco, W. A. Combined intraand extracellular immunization against human immunodeficiency virus type 1 infection with a human anti-gp120 antibody. Proc. Natl. Acad. Sci. U. S. A. 91, 5932-5936 (1994b).
25. Chen, L. H., Huang, Q., Wan, L., Zeng, L. Y., Li, S. F., Li, Y. P., Lu, X. F. & Cheng, J. Q.
Expression, purification, and in vitro refolding of a humanized single-chain Fv antibody against human CTLA4 (CD152). Protein Expr. Purif. 2, 495-502 (2006).
26. Duan, L., Zhang, H., Oakes, J. W., Bagasra, O. & Pomerantz, R. J. Molecular and virological effects of intracellular anti-Rev single-chain variable fragments on the expression of various human immunodeficiency virus-1 strains. Hum. Gene Ther. 5, 1315-1324 (1994a).
27. Duan, L. K., Bagasra, O., Laughlin, M. A., Oakes, J. W. & Pomerantz, R. J. Potent inhibition of human immunodeficiency virus type 1 replication by intracellular anti-Rev single chain antibody. Proc. Natl. Acad. Sci. U. S. A. 91, 5075-5079 (1994b).
28. Duan, L., Zhu, M., Bagasra, O. & Pomerantz, R. J. Intracellular immunization against HIV-1 infection of human T lymphocytes: utility of anti-Rev single chain variable fragments.
Hum. Gene Ther. 6, 1561-1573 (1995).
29. Edelman, G. M. Antibody structure and molecular immunology. Science 180, 830-840 (1973).
30. Glockshuber, R., Malia, M., Pfitzinger, I. & Pluckthun, A. A comparison of strategies to stabilize immunoglobulin Fv-fragments. Biochemistry 29, 1362-1367 (1990).
31. Glennie, M. J. & Van De Winkel, J. G. Renaissance of cancer therapeutic antibodies. Drug Discov. Today. 8, 503-510 (2003).
32. Glazebrook, J. S., Heasman, M. P. & De Beer, S. W. Picornalike viral particles associated
with mass mortalities in larval barramundi, Lates calcarifer (Bloch). J. Fish Dis. 13, 245-249 (1990).
33. Grotmol, S. & Totland, G. K. Surface disinfection of Atlantic halibut Hippoglossus hippoglossus eggs with ozonated sea-water inactivates nodavirus and increases survival of the larvae. Dis. Aquat. Organ. 39, 89-96 (2000).
34. Goncalvez, A. P., Men, R., Wernly, C., Purcell, R. H. & Lai, C. J. Chimpanzee Fab fragments and a derived humanized immunoglobulin G1 antibody that efficiently cross- neutralize dengue type 1 and type 2 viruses.J. Virol. 23, 12910-12918 (2004).
35. Huston, J. S., Levinson, D., Mudgett-Hunter, M., Tai, M. S., Novotny, J., Margolies, M. N., Ridge, R. J., Bruccoleri, R. E., Haber, E. & Crea, R. Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc. Natl. Acad. Sci. U. S. A. 85, 5879-5883 (1988).
36. Ho, W. Z., Lai, J. P., Bouhamdan, M., Duan, L., Pomerantz, R. J. & Starr, S. E. Inhibition of HIV type 1 replication in chronically infected monocytes and lymphocytes by retrovirus-mediated gene transfer of anti-rev single-chain variable fragments. AIDS Res.
Hum. Retroviruses 14, 1573-1580 (1998).
37. Inouye, R. T., Du, B., Boldt-Houle, D., Ferrante, A., Park, I. O., Hamer, S. M., Duan, L., Groopman, J. E., Pomerantz, R. J. & Terwilliger, F. Potent inhibition of human immunodeficiency virus type 1 in primary T cells and alveolar macrophages by combination anti-Rev strategy delivered in adeno associated virus vector. J. Virol. 71, 4071-4078 (1997).
38. Junker, U., Kalfoglou, C. S., Moon, J. J., Beck, M. K., Kaneshima, H. & Bo¨hnlein, E.
Inhibition of human immunodeficiency virus type 1 replication in myelomonocytic cells derived from retroviral vector-transduced peripheral blood progenitor cells. Hum. Gene Ther.
9, 333-340 (1998).
39. Juweid, M. E., Zhang, C. H., Blumenthal, R. D., Hajjar, G., Sharkey, R. M. & Goldenberg, D. M. Prediction of hematologic toxicity after radioimmunotherapy with (131)I-labeled anticarcinoembryonic antigen monoclonal antibodies. J. Nucl. Med. 40, 1609-1616 (1999).
40. Jaffers, G. J., Fuller, T. C., Cosimi, A. B., Russell, P. S., Winn, H. J. & Colvin, R. B.
Monoclonal antibody therapy. Anti-idiotypic and non-anti-idiotypic antibodies to OKT3
arising despite intense immunosuppression. Transplantation 41, 572-578 (1986).
41. Jones, P. T., Dear, P. H., Foote, J., Neuberger, M. S. & Winter, G. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature
321, 522-525 (1986).
42. Jain, R. K. Transport of molecules across tumor vasculature. Cancer Metastasis Rev. 6, 559-593 (1987).
43. Jia, L., Yu, J., Song, H., Liu, X., Ma, W., Xu, Y., Zhang, C., Dong, S. & Li, Q. Screening of human antibody Fab fragment against HBsAg and the construction of its dsFv form. Int. J.
Biol. Sci. 2, 103-110 (2008).
44. Kaku, S., Yano, S., Kawasaki, T., Sakai, Y., Suzuki, K. I., Kawamura, K., Masuho, Y., Satoh, N., Takenaka, T., Landolfi, N. F. & Co, M. S. Comparison of the antiplatelet agent potential of the whole molecule, F(ab’)2 and Fab fragments of humanized anti-GPIIb/IIIa monoclonal antibody in monkeys. Gen. Pharmacol. 27, 435 (1996).
45. Kim, S. H., Kim, S. H., Oh, H. K., Ryu, C. J., Park, S. Y. & Hong, H. J. In vivo hepatitis B virus-neutralizing activity of an anti-HBsAg humanized antibody in chimpanzees. Exp. Mol.
Med. 1, 145-149 (2008).
46. King, D. J., Turner, A., Farnsworth, A. P. H., Adair, J. R., Owens, R. J., Pedley, B., Baldock, D., Proudfoot, K. A., Lawson, A. D. G., Beeley, N. R. A., Millar, K., Millican, T. A., Boyce, B. A., Antoniw, P., Mountain, A., Begent, R. H. J., Shochat, D. & Yarranton, G.T. Improved tumour targeting with chemically cross-linked recombinant antibody fragments. Cancer Res.
54, 6176 (1994).
47. Kortt, A. A., Dolezal, Q., Power, B. E. & Hudson, P. J. Dimeric and trimeric antibodies:
high avidity scFvs for cancer targeting. Biomol. Eng. 18, 98-108 (2001).
48. Kwak, J. W., Choi, B. K., Lee, D. I., Kang, Y. K., Seo, Y. G., Cho, W. K. & Han, M. H.
Cloning and characterization of cDNAs coding for heavy and light chains of a monoclonal antibody (MabB23) specific for human plasma apolipoprotein B-100. Gene 169, 237-239 (1996).
49. Hsueh, P. R., Kao, C. L., Lee, C. N., Chen, L. K., Ho, M. S., Sia, C., Fang, X. D., Lynn, S., Chang, T. Y., Liu, S. K., Walfield, A. M. & Wang, C. Y. SARS antibody test for
serosurveillance. Emerg. Infect. Dis. 9, 1558-1562 (2004).
50. Lorenzen, N., Cupit, P. M., Einer-Jensen, K., Lorenzen, E., Ahrens, P., Secombes, C. J. &
Cunningham, C. Immunoprophylaxis in fish by injection of mouse antibody genes. Nat.
Biotechnol. 11, 1177-80 (2000a).
51. Lorenzen, N., Cupit, P. M., Secombes, C. J. & Cunningham, C. Three monoclonal antibodies to the VHS virus glycoprotein: comparison of reactivity in relation to differences in immunoglobulin variable domain gene sequences. Fish Shellfish Immunol. 2, 129-142 (2000b).
52. Lai, Y. S., John, J. A., Guo, I. C., Chen, S. C., Fang, K. & Chang, C. Y. In vitro efficiency of intra- and extracellular immunization with mouse anti-YGNNV antibody against yellow grouper nervous necrosis virus . Vaccine 20, 3221-3229 (2002).
53. Lai, Z. Z., Xiong, D. S., Fan, D. M., Peng, H., Xu, Y. F., Zhu, Z. P. & Yang, Y.Z. High expression of the chimeric antibody Fab against-CD20 in E coli and bioactivity determination. Zhongguo Mian Yi Xue Za Zhi 16, 521-524 (2000).
54. Liu, M. Y., Han, W., Ding, Y. L., Zhou, T. H., Tian, R. Y., Yang, S. L., Liu, H. & Gong, Y.
Generation and characterization of C305, a murine neutralizing scFv antibody that can inhibit BLyS binding to its receptor BCMA. Acta Biochim. Biophys. Sin. (Shanghai) 6, 415-42 (2005).
55. Lin, T. L., Clark, T. G. & Dickerson, H. Passive immunization of channel catfish (Ictalurus punctatus) against the ciliated protozoan parasite Ichthyophthirius multifiliis by use of murine monoclonal antibodies.Infect. Immun. 10, 4085-4090 (1996).
56. Lorenzen, N., Olesen, N. J. & VestergArd Jsrgensen, P. E. Production and characterization of monoclonal antibodies to four Egtved virus structural proteins. Dis. Aquat. Organ. 4, 35-42 (1988).
57. Marasco, W. A., Haseltine, W. A. & Chen, S. Y. Design, intracellular expression, and activity of a human anti-human immunodeficiency virus type 1 gp120 single-chain antibody.
Proc. Natl. Acad. Sci. U. S. A. 90, 7889-7893 (1993).
58. Marasco, W. A. Intrabodies: turning the humoral immune system outside in for intracellular immunization. Gene Ther. 4, 11-15 (1997).
59. Meredith, R. F., LoBuglio, A. F. & Spencer, E. B. Recent progress in radioimmunotherapy for cancer. Oncology 11, 979-984 (1997).
60. Mori, K., Nakai, T., Muroga, K., Arimoto, M., Mushiake, K. & Furusawa, I. Properties of a new virus belonging to Nodaviridae found in larval striped jack (Pseudocaranx dentex) with nervous necrosis. Virology 187, 368-371 (1992).
61. Munday, B. L., Langdon, J. S., Hyatt, A. & Humphrey, J. D. Mass mortality associated with a viral-induced vacuolating encephalopathy and retinopathy of larval and juvenile barramundi, Lates calcarifer Bloch. Aquaculture 103, 197-211 (1992).
62. Murray, J. L., Macey, D. J., Kasi, L. P., Rieger, P., Cunningham, J., Bhadkamkar, V., Zhang, H. Z., Schlom, J., Rosenblum, M. G. & Podoloff, D. A. Phase II radioimmunotherapy trial with 131I-CC49 in colorectal cancer. Cancer 73, 1057-1066 (1994).
63. Mukherjee, J., Scharff, M. D. & Casadevall, A. Protective murine monoclonal antibodies to Cryptococcus neoformans. Infect. Immun. 11, 4534-4541. (1992).
64. Newman, R., Alberts, J., Anderson, D., Carner, K., Heard, C., Norton, F., Raab, R., Re, V.
M., Shuey, S. & Hanna, N. Primatization" of recombinant antibodies for immunotherapy of human diseases: a macaque/human chimeric antibody against human CD4. Biotechnology
10, 1455-1460 (1992).
65. Nishizawa, T., Masaaki, K., Nakai, T. & Muroga, K. Comparison of the coat protein genes of five fish nodaviruses, the causative agent of nervous necrosis in marine fish. J. Gen. Virol.
76, 1563-1569 (1995).
66. Nishizawa, T., Furuhashi, T., Nagai, T., Nakai, T. & Muroga, K. Genomic classifIcation of fish nodaviruses by molecular phylogenetic analysis of the coat protein gene. Appl. Environ.
Microbiol. 63, 1633-1636 (1997).
67. OIE. Chapter 2.2.2. Viral encephalopathy and retinopathy. In: OIE Diagnostic Manual for Aquatic Animal Diseases, 3rd edn: 69-73 (2000).
68. Press, O. W. Radiolabeled antibody therapy of B-cell lymphomas. Semin. Oncol. 26, 58-65 (1999).
69. Quinn, M. J., Plow, E. F. & Topol, E. J. Platelet glycoprotein IIb/IIIa inhibitors: recognition
of a two-edged sword? Circulation 107, E39-9 (2003).
70. Qing, Y., Shuo, W., Zhihua, W., Huifen, Z., Ping, L., Lijiang, L., Xiaorong, Z., Liming, C., Daiwen, X., Yu, H., Wei, X., Min, F., Zuohua, F. & Guanxin, S. The in vitro antitumor effect and in vivo tumor-specificity distribution of human-mouse chimeric antibody against transferrin receptor. Cancer Immunol. Immunother.
55, 1111-21 (2005).
71. Roguska, M. A., Pedersen, J. T., Keddy, C. A., Henry, A. H., Searle, S. J., Lambert, J. M., Goldmacher, V. S., Blättler, W. A., Rees, A. R. & Guild, B. C. Humanization of murine monoclonal antibodies through variable domain resurfacing.Proc. Natl. Acad. Sci. U. S. A. 3, 969-73 (1994).
72. Riechmann, L., Foote, J. & Winter, G. Expression of an antibody Fv fragment in myeloma cells. J. Mol. Biol. 203, 825-828 (1988).
73. Reynolds, J. C., Del Vecchio, S., Sakahara, H., Lora, M. E., Carrasquillo, J. A., Neumann, R.
D. & Larson, S. M. Anti-murine antibody response to mouse monoclonal antibodies: clinical findings and implications. Int. J. Rad. Appl. Instrum B. 16, 121-125 (1989).
74. Rondon, I. J. & Marasco, W. A. Intracellular antibodies (intrabodies) for gene therapy of infectious disease. Annu. Rev. Microbiol. 51, 257-283 (1997).
75. Sears, H. F., Herlyn, D., Steplewski, Z. & Koprowski, H. Effects of monoclonal antibody immunotherapy on patients with gastrointestinal adenocarcinoma. J. Biol. 3, 138-150 (1984).
76. Shawler, D. L., Bartholomew, R. M., Smith, L. M. & Dillman, R. O. Human immune response to multiple injections of murine monoclonal IgG. J. Immunol. 135, 1530-1535 (1985).
77. Sherie, L., Morrison, M., Jacqueline Johnsont Leonard, A., Herzenbergt Vernon, T.
Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains. Proc. Natl. Acad. Sci. U. S. A. 81, 6851-6855 (1984).
78. Tavladoraki, P., Benvenuto, E., Trinca, S., De Martinis, D., Cattaneo, A. & Galeffi, P.
Transgenic plants expressing a functional single-chain Fv antibody are specifically protected from virus attack. Nature 366, 469-472 (1993).
79. Tewari, D., Goldstein, S. L., Notkins, A. L. & Zhou, P. cDNA encoding a single-chain antibody to HIV p17 with cytoplasmic or nuclear retention signals inhibits HIV-1 replication.
J. Immunol. 161, 2642-2647 (1998).
80. Winter, G. & Harris, W. J. Humanized antibodies. Immunol. 14, 243-246 (1993).
81. Waldmann, T. A. Monoclonal antibodies in diagnosis and therapy. Science 252, 1657-1662 (1991).
82. Wu, Y., Duan, L., Zhu, M., Hu, B., Kubota, S., Bagasra, O. & Pomerantz, R. J. Binding of intracellular anti-Rev single chain variable fragments to different epitopes of human immunodeficiency virus type 1 Rev: variations in viral inhibition. J. Virol. 70, 3290-3297 (1996).
83. Xia, L., Gu, J., Zhang, X., Liu, Y., Wan, H., Li, P. & Ruan, C. Preparation of an antifebrin thrombus-specific murine/human chimeric monoclonal antibody Fab fragment in Escherichia coli. Thromb. Res. 8, 477-484 (1996).
84. Yokota, T., Milenic, D. E., Whitlow, M. & Schlom, J. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res. 52, 3402-3408 (1992).
85. Yoshikoshi, K. & Inoue, K. Viral nervous necrosis in hatchery-reared larvae and juveniles of Japanese parrotfish, Oplegnathus fasciatus (Temminck & Schlegel). J. Fish Dis. 13, 69-77 (1990).
86. Yoshimizu, M., Suzuki, K., Nishizawa, T., Winton, J. R. & Ezura, Y. Antibody screening for the identification of nervous necrosis carriers in flounder broodstock. In: Proceedings NRIA International Workshop on New Approaches to Viral Diseases of Aquatic Animals. Kyoto, p 124-130 (1997).
87. Zhou, P., Goldstein, S., Devadas, K., Tewari, D. & Notkins, A. L. Cells transfected with a non-neutralizing antibody gene are resistant to HIV infection: targeting the endoplasmic reticulum and trans-Golgi network. J. Immunol. 160, 1489-1496 (1998).